Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can this new drug safely reverse a blood thinner? early trial underway

NCT ID NCT07202663

Completed Knowledge-focused Sponsor: Basking Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety of a new drug called BB-025, designed to reverse the effects of another experimental drug, BB-031. 72 healthy volunteers received either BB-025 or a placebo, alone or after BB-031, and were monitored for 28 days. The main goal was to check for side effects and measure how the drugs move through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BB-025 (reversal agent) and BB-031 (RNA aptamer)
What this could lead to
If successful, this could lead to a way to quickly reverse the effects of BB-031, which might be used as a blood thinner.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug levels, not whether the reversal agent works in a real medical emergency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ischemic Stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS PHARMACODYNAMICS PHARMACOKINETICS

Contacts and locations

Locations

  • Scintia Clinical Research Ltd

    Randwick, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.